Indications for DDAVP NASAL SPRAY:
Central diabetes insipidus.
Individualize. 10–40mcg once daily into 1 nostril (or 40mcg divided into 2–3 daily doses). Use other forms for doses <10mcg or doses other than multiples of 10mcg.
<4yrs: not recommended. Individualize. ≥4yrs: initially 10mcg once daily into 1 nostril; may increase to 30mcg once daily (or in 2 divided doses, usually 20mcg in the AM and 10mcg in the PM). Use other forms for doses <10mcg.
DDAVP NASAL SPRAY Contraindications:
Moderate to severe renal impairment (CrCl <50mL/min). Hyponatremia, or history of.
DDAVP NASAL SPRAY Warnings/Precautions:
Monitor fluid intake, urine volume and osmolality. Fluid/electrolyte imbalance (eg, cystic fibrosis). Habitual or psychogenic polydipsia. Coronary artery insufficiency. Hypertension. Inj: Predisposition to thrombosis. Nasal mucosal abnormalities (nasal forms). Young children. Elderly. Pregnancy. Nursing mothers.
DDAVP NASAL SPRAY Classification:
DDAVP NASAL SPRAY Interactions:
Caution with other pressor agents, drugs that may increase the risk of water intoxication with hyponatremia (eg, tricyclic antidepressants, SSRIs, chlorpromazine, opiates, NSAIDs, lamotrigine, carbamazepine). Possible convulsions with oxybutynin, imipramine.
Headache, nausea, flushing, abdominal cramps, vulval pain, water intoxication, hyponatremia, nasal congestion or rhinitis (nasal forms), inj site reaction; rare: changes in BP, severe allergic reactions, seizures in children from plasma hypoosmolality, thrombotic events (inj).
Tabs—100; Rhinal tube—2.5mL (w. 2 rhinal tubes); Amp (1mL)—10; Multi-dose vial (10mL)—1; Nasal spray—5mL (50 sprays)